New gadget boosts fluid removal for kidney patients on home dialysis
NCT ID NCT05874804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a device called Carry Life UF in 28 adults with end-stage kidney disease who use continuous ambulatory peritoneal dialysis (CAPD) at home. The device adds glucose to the dialysis fluid already in the belly to help remove more fluid over a 5-hour session. Researchers compared how much fluid was removed with the device versus a standard high-glucose dialysis bag. The goal was to see if the device could improve fluid removal without increasing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carry Life UF device
What this could lead to
If successful, this device could help kidney dialysis patients remove more fluid during treatment, potentially improving fluid balance without needing stronger dialysis solutions.
What could go wrong
This was a small, early-stage study with only 28 participants. The device adds complexity to standard dialysis, and long-term safety or benefit is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST-Cremona
Cremona, Italy
-
Heartlands Hospital
Birmingham, United Kingdom
-
Karolinska Universitetssjukhuset, Njurmedicin Rosenlund
Stockholm, Sweden
-
King's College Hospital
London, United Kingdom
-
London Royal Hospital, Barth Health NHS Trust
London, United Kingdom
-
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
-
Polyclinic Milan
Milan, Italy
-
Queen Elisabeth's Hospital
Birmingham, United Kingdom
-
Royal Free London NHS Foundation Trust
London, United Kingdom
-
Sahlgrenska Universitetssjukhuset
Gothenburg, Sweden
-
Skånes University Hospital
Lund, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells aim to trick the body into accepting a new kidney
- Could removing a catheter sooner after kidney transplant cut infection risk?
- Could a bone marrow infusion help kidney transplant patients ditch lifelong pills?
- Could a stem cell infusion free kidney transplant patients from lifelong drugs?
- Mobile coaching may help dialysis patients shed excess fluid
- Can a Nurse-Led program reverse frailty in dialysis patients?